| Similar Articles |
|---|
 |
The Motley Fool
February 1, 2008
Brian Lawler |
Alexion Looks for a Bigger Niche Alexion Pharmaceutical announces sales of its rare blood disorder medication should expand in 2008.   |
Chemistry World
May 12, 2015
Phillip Broadwith |
Alexion to buy Synageva for rare disease drugs Rare disease drugmaker Alexion has agreed to buy US biotech Synageva for $8.4 billion in a mix of cash and shares. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
The Motley Fool
August 31, 2011
Brian Orelli |
Shire Enters a Crowded Market Last week, the FDA approved Shire Pharmaceuticals' Firazyr to treat a rare genetic disease. |
The Motley Fool
May 1, 2008
Brian Lawler |
Soliris Brightens Alexion's Quarter Alexion Pharmaceuticals' lone drug posts gargantuan growth. |
The Motley Fool
November 27, 2009
Brian Orelli |
Biotech Bargains for Your Portfolio Everyone is looking for bargains this time of year. That includes pharmaceutical giants looking to pick up some biotechs on the discount rack, and investors trying to get there first. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy. |
Chemistry World
September 11, 2012
Maria Burke |
Orphan drugs set for 'tremendous growth' A new report by Thomson Reuters offers clear confirmation that developing drugs for rare, or orphan, diseases is economically attractive, despite the smaller patient pool. |
The Motley Fool
July 21, 2011
Tim Beyers |
Alexion Pharmaceuticals Shares Popped: What You Need to Know Shares of Alexion Pharmaceuticals rose close to 11% in early trading and touched a new 52-week high of $57.73 a share after the biotech company raised its full-year forecast. |
The Motley Fool
January 27, 2006
Stephen D. Simpson |
A Real Triumph for Alexion A powerful clinical result brings FDA approval into sight for this biotech company. Investors, enjoy the day -- this is what makes biotech investing fun and exciting. |
Managed Care
July 2003
John Carroll |
CMS Move Threatens To Put Orphan Drugs Out in Cold Have drug companies lost the incentive to develop products for small populations? What's managed care's stake? |
The Motley Fool
April 30, 2007
Brian Lawler |
Alexion Heads Overseas Alexion is headed for approval of its lead compound in the European Union. With no other compounds in clinical stage development, an investment in Alexion is all about the market potential for Soliris. |
The Motley Fool
August 9, 2011
Brian Orelli |
Give Avanir Some Time It's going to need it. |
The Motley Fool
November 2, 2006
Brian Lawler |
BioMarin's in Good Health This biopharma has a leg up on the competition by getting its finances in order. Even with its small pipeline, BioMarin appears to be running smoothly. Investors, take note. |
The Motley Fool
May 21, 2007
Brian Lawler |
DUSA's Orphan Isn't Unique The pharmaceutical gets "orphan drug" status for its lead compound. Investors, take note. |
The Motley Fool
July 31, 2009
Brian Orelli |
The Little Orphan That Could After a rough start to the year, Rule Breakers pick BioMarin Pharmaceutical is back on track. |
The Motley Fool
November 4, 2005
Stephen D. Simpson |
A $99 Biotech Portfolio Can this biotech six-pack pay off for aggressive investors? Acadia Pharmaceuticals... Alexion Pharmaceuticals... Arena Pharmaceuticals... Crucell NV... DOV Pharmaceutical... Millennium Pharmaceuticals... |
Pharmaceutical Executive
September 1, 2008
Jeffrey S. Aronin |
The Orphan Opportunity The Orphan Drug Act was passed 25 years ago. But the challenge of actually getting rare disease drugs and therapies to patients still remains |
The Motley Fool
February 28, 2011
Brian Orelli |
Rare Diseases, Big Opportunity "Orphan" drugs to keep your eye on. |
The Motley Fool
July 16, 2008
Brian Lawler |
A Big Move From ViroPharma ViroPharma picks up an asset that's more than half its size. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
The Motley Fool
November 24, 2010
Sean Williams |
ViroPharma: Bargain or Value Trap? Generic competition and production issues are major red flags. |
The Motley Fool
February 27, 2007
Brian Lawler |
Mostly Good From BioMarin Drugmaker BioMarin updates investors on its drug pipeline and quarterly financial results. |
The Motley Fool
March 27, 2009
Brian Orelli |
Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with. |
The Motley Fool
January 12, 2012
Selena Maranjian |
Make Money in Growing Health-Care Stocks the Easy Way Demand will only rise with a growing and aging population. |
The Motley Fool
August 6, 2008
Brian Lawler |
BioMarin's New Drugs Mostly Hit Their Targets Near-term volatility in a drugmaker's shares can make for long-term opportunities. Such is the current case with BioMarin Pharmaceutical. |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Endo Pharmaceuticals Holdings Burn You? Endo Pharmaceuticals Holdings is cash flow-positive, and has been for quite some time. That's investment nirvana for biotech shareholders. |
Pharmaceutical Executive
May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short. |
The Motley Fool
April 1, 2008
Brian Lawler |
BioMarin Drug Heads Overseas One of the pharmaceutical's enzyme replacement therapy drugs gets approved in Japan. |
The Motley Fool
July 14, 2005
Stephen D. Simpson |
Dueling Fools: Protein Design Labs Bear Protein Design Labs could be a big winner, or a major loser. The biotech has a strong business, but today's stock price isn't "great." |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
The Motley Fool
May 5, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. |
The Motley Fool
August 26, 2010
Travers & Jayson |
Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing? |
The Motley Fool
September 10, 2011
Rex Moore |
Let's See If Alexion's Growth Is for Real Alexion Pharmaceuticals appears to be in good shape in terms of the intangible assets ratio and tangible book value. |
The Motley Fool
December 7, 2011
Brian Orelli |
As the Biotech Saying Goes... Another delay for Protalix BioTherapeutics makes you think. |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
January 5, 2012
Brian Orelli |
Are These Biotech Drug Launches Back on Track? With the annual health-care conference starting up next week, Dendreon and InterMune announced preliminary fourth-quarter sales today. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
Pharmaceutical Executive
December 1, 2013
Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. |
The Motley Fool
February 22, 2006
Stephen D. Simpson |
Axcan Kicked in the Guts The failure of a phase 3 trial puts future growth prospects for Canadian specialty pharmaceutical AxcanPharma in doubt. Investors, take note. |
The Motley Fool
February 10, 2005
Karl Thiel |
The Worst Has Happened. Time to Sell? Biotech stocks can be volatile, but dumping them in response to bad news isn't always the smartest option: Axonyx... Icos Pharmaceuticals... etc. |
The Motley Fool
November 29, 2010
Travis Hoium |
Protalix BioTherapeutics Shares Popped: What You Need to Know Shares of biopharmaceutical company Protalix BioTherapeutics jumped 10% this morning after the company announced a European application for taliglucerase alfa. |
The Motley Fool
September 20, 2004
W.D. Crotty |
Does This Biotech Belong in Bargain Bin? Maxim Pharmaceutical's Ceplene produces disappointing results. Stocks are down more than 50%. |
